About 20n
20n is a company based in San Francisco (United States) founded in 2013. 20n has raised $2.22 million across 2 funding rounds from investors including Khosla Ventures, Y Combinator and Blumberg Capital. 20n operates in a competitive market with competitors including Amyris, Inscripta, Pivot Bio, Ginkgo Bioworks and Syngenta, among others.
- Headquarter San Francisco, United States
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.22 M (USD)
in 2 rounds
-
Latest Funding Round
$2.1 M (USD), Seed
May 01, 2015
-
Investors
Khosla Ventures
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of 20n
20n has successfully raised a total of $2.22M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $2.1 million completed in May 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in 20n
20n has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Khosla Ventures, Y Combinator and Blumberg Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage startups are accelerated via funding and educational programs.
|
Locked | Locked | Locked | |
|
Early-stage startups are funded by this venture capital firm.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in early and growth stage technology companies.
|
Locked | Locked | Locked |
Investor details for 20n
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by 20n
Investment portfolio details for 20n
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - 20n
Detailed financials for 20n
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
20N Comparisons
Peer comparison for 20n
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of 20n
20n operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Inscripta, Pivot Bio, Ginkgo Bioworks and Syngenta, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of renewable products for industrial solutions
|
|
| Locked | Locked | Locked |
Speech recognition solutions are provided by Inscripta for healthcare professionals.
|
|
| Locked | Locked | Locked |
Nitrogen-fixing microbes for corn crop nutrition are developed and applied.
|
|
| Locked | Locked | Locked |
Gene editing-based cultured ingredients are provided for agriculture.
|
|
| Locked | Locked | Locked |
Crop protection solutions and hybrid seeds are provided for farming.
|
|
| Locked | Locked | Locked |
Provider of integrated suite for advanced genetic design and manufacturing
|
Detailed competitors of 20n
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on 20N
Complete news archive for 20n
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about 20n
20n was founded in 2013 and raised its 1st funding round 1 year after it was founded.
20n is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
20n is a funded company, having raised a total of $2.22M across 2 funding rounds to date.
Founded in 2013 in San Francisco, United States, the company operates in the synthetic biology sector. Microbes such as E. coli and yeast are engineered with a mushroom-derived gene and over-expressed native genes PabABC and nhoA to convert sugar into acetaminophen. DNA blueprints depicting enzymatic pathways are provided. Data mining, machine learning, program synthesis, and natural language processing are combined to advance biotechnology applications.
20n has 4 investors. Key investors include Khosla Ventures, Y Combinator, Blumberg Capital, and Great Oaks Venture Capital.